Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | PKM | P14618 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | RXFP3 | Q9NSD7 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | CLK1 | P49759 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27599365 | 0.90 | MAPT (0.67) | MAPTPKMHTTRXFP3ALDH1A1 | |
| SCHEMBL5842614 | 0.86 | MAPT (0.74) | MAPTPKMHTTRXFP3ALDH1A1 | |
| SCHEMBL5841229 | 0.86 | ALDH1A1 (0.68) | MAPTPKMHTTRXFP3ALDH1A1 | |
| SCHEMBL5841181 | 0.84 | MAPT (0.72) | MAPTPKMHTTRXFP3ALDH1A1 | |
| SCHEMBL27599370 | 0.83 | MAPT (0.69) | MAPTPKMHTTRXFP3ALDH1A1 | |
| SCHEMBL5842333 | 0.82 | ALDH1A1 (0.51) | MAPTPKMHTTRXFP3ALDH1A1 | |
| SCHEMBL5842690 | 0.81 | SMN1; SMN2 (0.57) | MAPTHTTRXFP3ALDH1A1SMN1; SMN2 | |
| SCHEMBL5841923 | 0.80 | ALDH1A1 (0.51) | MAPTPKMHTTRXFP3ALDH1A1 | |
| SCHEMBL5842943 | 0.80 | RXFP3 (0.51) | MAPTPKMHTTRXFP3ALDH1A1 | |
| SCHEMBL5841935 | 0.78 | ALDH1A1 (0.47) | MAPTHTTALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100534990-C | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-02 | — | — | CN | disclosed |
| US-7067549-B2 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2006-06-27 | — | — | US | disclosed |
| US-20050192292-A1 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2005-09-01 | — | — | US | disclosed |
| CN-1610678-A | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS LTD (CH) | 2005-04-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192292-A1 | Pyrrolidone carboxamides | NPY1R, NPY5R, NPY2R | MAPT 4395/4885PKM 2585/4885HTT 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.